Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | CTSK | P43235 | 2/20 | 0.33 |
| ▸ | HMGCR | P04035 | 2/20 | 0.33 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | NOS1 | P29475 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | FDPS | P14324 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5575508 | 0.86 | CYP3A4 (0.38) | POLBCYP3A4CYP2C9CYP2C19GAA | |
| SCHEMBL908329 | 0.84 | CYP3A4 (0.36) | CYP3A4CYP2C9CYP2C19GAACTSK | |
| SCHEMBL1051880 | 0.82 | POLB (0.53) | POLBCYP3A4CYP2C9CYP2C19GAA | |
| SCHEMBL6819825 | 0.82 | GAA (0.36) | POLBCYP3A4CYP2C9CYP2C19GAA | |
| SCHEMBL4807731 | 0.82 | GAA (0.39) | POLBCYP3A4CYP2C9CYP2C19GAA | |
| SCHEMBL1238981 | 0.81 | BTN3A1 (0.33) | CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL13641232 | 0.81 | FDPS (0.38) | POLBGAACTSKCTSSNOS1 | |
| SCHEMBL23578550 | 0.81 | GAA (0.35) | POLBCYP3A4CYP2C9CYP2C19GAA | |
| SCHEMBL25801646 | 0.81 | ALDH1A1 (0.41) | POLBCYP3A4CYP2C9CYP2C19GAA | |
| SCHEMBL28336011 | 0.80 | MEN1 (0.54) | POLBGAACTSKMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150313889-A1 | HETEROARYLCARBOXYLIC ACID ESTER DERIVATIVE | AJINOMOTO CO., INC. (JP) | 2015-11-05 | — | — | US | disclosed |
| US-20150313889-A1 | HETEROARYLCARBOXYLIC ACID ESTER DERIVATIVE | AJINOMOTO CO., INC. (JP) | 2015-11-05 | — | — | US | disclosed |
| US-9115107-B2 | Heteroarylcarboxylic acid ester derivative | AJINOMOTO CO., INC. (JP) | 2015-08-25 | — | — | US | disclosed |
| US-9115107-B2 | Heteroarylcarboxylic acid ester derivative | AJINOMOTO CO., INC. (JP) | 2015-08-25 | — | — | US | disclosed |
| EP-2511271-B1 | HETEROARYLCARBOXYLIC ACID ESTER DERIVATIVE | AJINOMOTO KK (JP) | 2015-01-21 | — | — | EP | disclosed |
| US-20150011511-A1 | HETEROARYLCARBOXYLIC ACID ESTER DERIVATIVE | AJINOMOTO CO., INC. (JP) | 2015-01-08 | — | — | US | disclosed |
| US-20150011511-A1 | HETEROARYLCARBOXYLIC ACID ESTER DERIVATIVE | AJINOMOTO CO., INC. (JP) | 2015-01-08 | — | — | US | disclosed |
| US-8877805-B2 | Heteroarylcarboxylic acid ester derivative | AJINOMOTO CO., INC. (JP) | 2014-11-04 | — | — | US | disclosed |
| US-8877805-B2 | Heteroarylcarboxylic acid ester derivative | AJINOMOTO CO., INC. (JP) | 2014-11-04 | — | — | US | disclosed |
| US-20140080790-A1 | HETEROARYLCARBOXYLIC ACID ESTER DERIVATIVE | AJINOMOTO CO., INC. (JP) | 2014-03-20 | — | — | US | disclosed |
| US-20140080790-A1 | HETEROARYLCARBOXYLIC ACID ESTER DERIVATIVE | AJINOMOTO CO., INC. (JP) | 2014-03-20 | — | — | US | disclosed |
| US-8609715-B2 | Heteroarylcarboxylic acid ester derivative | AJINOMOTO CO., INC. (JP) | 2013-12-17 | — | — | US | disclosed |
| US-20120283222-A1 | HETEROARYLCARBOXYLIC ACID ESTER DERIVATIVE | AJINOMOTO CO., INC. (JP) | 2012-11-08 | — | — | US | disclosed |
| US-20120283222-A1 | HETEROARYLCARBOXYLIC ACID ESTER DERIVATIVE | AJINOMOTO CO., INC. (JP) | 2012-11-08 | — | — | US | disclosed |
| EP-2511271-A1 | HETEROARYLCARBOXYLIC ACID ESTER DERIVATIVE | AJINOMOTO CO., INC. (JP) | 2012-10-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140080790-A1 | HETEROARYLCARBOXYLIC ACID ESTER DERIVATIVE | DPP4, DPP9, DPP7 | POLB 4531/4885CYP3A4 141/4885CYP2C9 257/4885 |
| US-20120283222-A1 | HETEROARYLCARBOXYLIC ACID ESTER DERIVATIVE | DPP4, DPP9, DPP7 | POLB 4531/4885CYP3A4 141/4885CYP2C9 257/4885 |
| US-20150011511-A1 | HETEROARYLCARBOXYLIC ACID ESTER DERIVATIVE | DPP4, DPP9, DPP7 | POLB 4531/4885CYP3A4 141/4885CYP2C9 257/4885 |
| US-20150313889-A1 | HETEROARYLCARBOXYLIC ACID ESTER DERIVATIVE | DPP4, DPP9, DPP7 | POLB 4531/4885CYP3A4 141/4885CYP2C9 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.